Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update
GlobeNewswire
· Total revenues in Q1 2024 increased to $37 million compared to $16 million in the same period last year· Gross margin in Q1..
· Total revenues in Q1 2024 increased to $37 million compared to $16 million in the same period last year· Gross margin in Q1..
*Gross Margin of Continuing Operations^[**^1]**Improved by 0.3ppt and Net Margin of Continuing Operations to Shareholders Narrowed..
· SIMLANDI is the first interchangeable high-concentration, citrate-free biosimilar to Humira^®REYKJAVIK, Iceland and PARSIPPANY,..